Dosage Form Design for Oral Administration

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1667

Special Issue Editors


E-Mail Website
Guest Editor
Department of Clinical, Pharmaceutical and Biological Sciences, School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK
Interests: 3D printing; drug delivery; pharmaceutical formulation; digital health

E-Mail Website
Guest Editor
Global Business School for Health, UCL East, 7 Sidings Street, London E20 2AE, UK
Interests: taste masking; electrospinning; nanofabrication; age-appropriate; QbD; taste assessment

Special Issue Information

Dear Colleagues,

We extend a warm invitation to you to contribute to our forthcoming Special Issue entitled "Dosage Form Design for Oral Administration" in the esteemed journal Pharmaceutics. This Special Issue represents a significant opportunity to explore the latest developments in the design of oral medications and their impact on the field of pharmaceutical sciences.

Our Special Issue seeks to showcase recent advancements in the field of oral medication design. Aligned with the core focus of Pharmaceutics, spanning the topics of pharmaceutical formulation, drug design, and manufacturing processes, we welcome the submission of original research articles and reviews. Potential research areas include, but are not limited to:

  • Novel age-appropriate dosage forms, particularly designed for special populations, such as mini-tablets and orally disintegrating dosage forms;
  • Controlled drug delivery systems tailored for site-specific administration within the gastrointestinal tract;
  • Leveraging nanotechnology in the design and manufacturing of oral dosage forms, with a focus on enhancing dissolution profiles;
  • Innovations in the oral delivery of therapeutic proteins and peptides, including via buccal and sublingual routes;
  • Advancements in oral vaccine delivery with the aim of expanding global healthcare accessibility;
  • Research focused on taste-masking strategies for the oral delivery of bitter pharmaceuticals;
  • Specialized packaging solutions for unique oral dosage forms;
  • Implementation of Quality by Design methodologies for the design of oral dosage forms;
  • Progress in the design and manufacturing of oral delivery systems for veterinary medicines;
  • Advanced manufacturing technologies for oral drug administration.

This Special Issue offers an exceptional platform for researchers, scientists, and practitioners to share their findings and enrich our collective understanding of oral dosage form design. We eagerly anticipate your valuable contributions and active participation.

Dr. Atheer Awad
Dr. Hend Abdelhakim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • controlled release
  • nanotechnology
  • peptide and protein
  • buccal
  • age-appropriate
  • taste
  • packaging
  • mini-tablets
  • quality by design
  • veterinary medicine

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 7797 KiB  
Article
Simultaneous Delivery of Curcumin and Resveratrol via In Situ Gelling, Raft-Forming, Gastroretentive Formulations
by Worrawee Siripruekpong, Rachanida Praparatana, Ousanee Issarachot and Ruedeekorn Wiwattanapatapee
Pharmaceutics 2024, 16(5), 641; https://doi.org/10.3390/pharmaceutics16050641 - 10 May 2024
Viewed by 390
Abstract
Curcumin and resveratrol are polyphenolic compounds that have been shown to exhibit synergistic therapeutic properties including anti-inflammatory, anticancer, and antiulcer activities, which may be exploited for the treatment of gastric diseases. However, both compounds have poor aqueous solubility and rapid metabolism, resulting in [...] Read more.
Curcumin and resveratrol are polyphenolic compounds that have been shown to exhibit synergistic therapeutic properties including anti-inflammatory, anticancer, and antiulcer activities, which may be exploited for the treatment of gastric diseases. However, both compounds have poor aqueous solubility and rapid metabolism, resulting in a low oral bioavailability. In situ gelling, liquid formulations were developed to produce a gastroretentive, raft-forming delivery vehicle to improve bioavailability. Solid dispersions containing a mixture of curcumin and resveratrol with Eudragit® EPO (Cur/Res-SD) were first prepared using solvent evaporation, to improve the solubility and dissolution of the compounds. Solid dispersions of a weight ratio of 1:10 curcumin/resveratrol to Eudragit® EPO were subsequently incorporated into in situ gelling, liquid formulations based on the gelling polymers, sodium alginate (low viscosity and medium viscosity), pectin, and gellan gum, respectively. Calcium carbonate and sodium bicarbonate were included to produce carbon dioxide bubbles in the gel matrix, on exposure to gastric fluid, and to achieve flotation. Moreover, the calcium ions acted as a crosslinking agent for the hydrogels. Optimized formulations floated rapidly (<60 s) in simulated gastric fluid (pH = 1.2) and remained buoyant, resulting in the gradual release of more than 80% of the curcumin and resveratrol content within 8 h. The optimized formulation based on medium-viscosity sodium alginate exhibited enhanced cytotoxic activity toward human gastric adenocarcinoma cell lines (AGS), compared with unformulated curcumin and resveratrol compounds, and increased anti-inflammatory activity against RAW 264.7 macrophage cells compared with the NSAID, indomethacin. These findings demonstrate that in situ gelling, liquid formulations, loaded with a combination of curcumin and resveratrol in the form of solid dispersions, show potential as gastroretentive delivery systems for local and systemic effects. Full article
(This article belongs to the Special Issue Dosage Form Design for Oral Administration)
Show Figures

Figure 1

17 pages, 13528 KiB  
Article
Taste-Masked Pellets of Warfarin Sodium: Formulation towards the Dose Personalisation
by Lakija Kovalenko, Kirils Kukuls, Marta Berga and Valentyn Mohylyuk
Pharmaceutics 2024, 16(5), 586; https://doi.org/10.3390/pharmaceutics16050586 - 26 Apr 2024
Viewed by 739
Abstract
The bitter drug, warfarin, has a narrow therapeutic index (NTI) and is used in paediatrics and geriatrics. The aim of this feasibility study was to formulate the taste-masked warfarin-containing pellets to be applicable for dose personalisation and to improve patient compliance, as well [...] Read more.
The bitter drug, warfarin, has a narrow therapeutic index (NTI) and is used in paediatrics and geriatrics. The aim of this feasibility study was to formulate the taste-masked warfarin-containing pellets to be applicable for dose personalisation and to improve patient compliance, as well as to investigate the effect of the core type (PharSQ® Spheres M, CELPHERE™ CP-507, and NaCl) on the warfarin release from the Kollicoat® Smartseal taste-masking-coated pellets. The cores were successfully drug-loaded and coated in a fluid-bed coater with a Wurster insert. An increase in particle size and particle size distribution was observed by optical microscopy. In saliva-simulated pH, at the Kollicoat® Smartseal level of 2 mg/cm2, none of the pellets demonstrated drug release, confirming their efficient taste-masking. However, in a stomach-simulated pH, a faster drug release was observed from PharSQ® Spheres M- and CELPHERE™ CP-507-coated pellets in comparison with NaCl cores. Additional experiments allowed us to explain the slower drug release from NaCl-containing pellets because of the salting-out effect. Despite the successful taste masking, the drug release from pellets was relatively slow (not more than 91% per 60 min), allowing for further formulation improvements. Full article
(This article belongs to the Special Issue Dosage Form Design for Oral Administration)
Show Figures

Graphical abstract

Back to TopTop